OFD Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

OFD Biopharma, a division of OFD Life Sciences, is a US-based CDMO providing expert lyophilization solutions to stabilize complex pharmaceuticals. The company differentiates itself through its focus on bulk lyophilization and proprietary platforms like LyoLock and LyoPastille, which aim to enhance drug stability, solubility, and bioavailability. It offers end-to-end support from R&D through commercialization, serving clients in oncology, immunology, and other therapeutic areas. As a private service provider, its financial model is based on client contracts and project milestones.

OncologyImmunologyInfectious DiseaseGastrointestinalCentral Nervous System

Technology Platform

Specialized lyophilization (freeze-drying) services with proprietary platforms for bulk preservation (LyoLock) and oral drug delivery (LyoPastille).

Opportunities

The rapid growth of complex biologics and cell/gene therapies, which often require advanced stabilization, creates strong demand for specialized lyophilization expertise.

The company's focus on bulk processing and innovative delivery formats like LyoPastille positions it to capture niche markets seeking improved drug stability and patient compliance.

Risk Factors

Heavy reliance on the success and funding of client drug programs creates revenue volatility.

The company operates in a highly competitive CDMO landscape where larger players may have broader service offerings and greater resources, posing a threat to market share and pricing power.

Competitive Landscape

OFD Biopharma competes within the formulation and lyophilization segment of the broader CDMO market. Key competitors include large, full-service CDMOs (e.g., Catalent, Lonza, Thermo Fisher Scientific) with lyophilization capabilities, as well as specialized formulation science firms. Its differentiation is its stated focus on bulk ('outside the vial') lyophilization and proprietary oral delivery technology.

More companies in Biologics / Biosimilars →More companies in United States →